Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$31.32
+3.4%
$36.46
$29.31
$61.38
$3.74B0.811.60 million shs1.41 million shs
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$172.36
$171.30
$21.83
$172.46
$6.58B1.421.09 million shsN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$6.52
+0.6%
$7.19
$4.62
$13.47
$408.29M0.21.19 million shs736,464 shs
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$21.44
-0.4%
$22.70
$16.60
$28.47
$1.57B1.84868,527 shs759,424 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+3.43%+2.72%-24.15%-31.91%-34.56%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
+0.62%-1.36%-14.21%-10.68%-39.96%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
-0.37%+1.04%-16.83%-3.90%+0.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.0189 of 5 stars
4.51.00.04.62.60.80.0
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.6241 of 5 stars
3.01.00.04.02.11.71.3
Schrödinger, Inc. stock logo
SDGR
Schrödinger
2.2709 of 5 stars
3.51.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.94
Moderate Buy$73.71135.36% Upside
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00
N/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2.06
Hold$8.8735.99% Upside
Schrödinger, Inc. stock logo
SDGR
Schrödinger
3.00
Buy$32.8052.99% Upside

Current Analyst Ratings Breakdown

Latest CYTK, SDGR, RETA, and SAGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/25/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/24/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$55.00
4/21/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$19.22M194.63N/AN/A($3.94) per share-7.95
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$23.48M280.05N/AN/A($1.79) per share-96.29
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$47.40M8.61N/AN/A$7.56 per share0.86
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$230.49M6.83$0.57 per share37.42$7.60 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%8/14/2025 (Estimated)
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
-$311.90MN/A0.00N/AN/AN/A-922.50%-73.39%N/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)

Latest CYTK, SDGR, RETA, and SAGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Schrödinger, Inc. stock logo
SDGR
Schrödinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
5.93
9.28
9.28
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.84
3.21
3.19
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
7.42
7.42
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
79.05%

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
26.80%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million114.00 millionOptionable
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
32138.15 million27.93 millionOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million58.10 millionOptionable
Schrödinger, Inc. stock logo
SDGR
Schrödinger
79073.38 million66.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$31.32 +1.04 (+3.43%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$32.25 +0.93 (+2.98%)
As of 05/29/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Reata Pharmaceuticals stock logo

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$6.52 +0.04 (+0.62%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$6.49 -0.03 (-0.52%)
As of 05/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Schrödinger stock logo

Schrödinger NASDAQ:SDGR

$21.44 -0.08 (-0.37%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$21.30 -0.14 (-0.67%)
As of 05/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.